Clinical Trials
5 trialsNCT02411656 2026-01-23
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02971748 2026-01-22
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03515798 2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2 Active not recruiting
NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05093387 2022-11-15
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Northwestern University
Phase 1 Withdrawn